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To the Editor:
Migraine is a serious public health problem that was
shown to affect 8.7 million women and 2.6 million men
in the United States yearly.1 In 2016, the global age
standardized prevalence of migraine was 14.4% causing 45.1 million years lived with disability.2
Migraine treatment includes analgesics and more
specifically triptans among other options.3 Naratriptan, a serotonin (5HT) receptor agonist, is a commonly
used one with a dose ranging between 1 and 2.5 mg
that can be repeated in 4 hours if no relief was
achieved.4–6 Paresthesia, nausea, dizziness, drowsiness, and fatigue are among the most common adverse
effects of naratriptan.6
Migraine is an established stroke risk factor.7,8 One
study showed that migraineurs with aura were 67%
more likely to suffer from stroke compared with nonmigraineurs.9,10 Several pathogenic mechanisms of
stroke in migraineurs were proposed including mainly
cortical spreading depression and other mechanisms
including inflammatory and vascular factors.7
Recent literature studying the adverse cardiovascular outcomes of triptans failed to show an increased
risk of strokes in patients using triptans.9,11,12 Nonetheless, the use of triptans in patients with history of
stroke is contraindicated.6
In this article, we describe a case of spinal infarction
in the setting of naratriptan overuse, an adverse event
not previously described in the literature.
A woman in her forties with history of chronic
migraine without aura was taking naratriptan 2.5 mg
as needed for her migraines. She had no vascular risk
factors, medical comorbidities. Two weeks before presentation, she has received the flu vaccine and had
some flu-like symptoms. On the day of symptom
onset, she took twice the amount of her prescribed
naratriptan dosage for a severe migraine and after 2
hours with still no relief, she then took another 2.5 mg.
Later that day, she developed numbness in her legs
followed by severe leg weakness, urinary retention,
and thoracic chest pain. Her examination showed flaccid lower extremities and a T4 sensory level with initially absent reflexes, which later became hyperreflexic. MRI scans showed T3 to T6 spinal infarction
with restricted diffusion on diffusion-weighted

imaging and T2 hyperintensity within the anterior spinal artery distribution (Figure 1). Echocardiogram did
not show evidence of Patent Foramen Ovale (PFO).
Her spinal fluid analysis was normal and the rest of
the neural axis imaging was negative for abnormal
lesions. She was given 5 days of IV methylprednisolone 1 g daily for the possibility of transverse myelitis
with no response. An extensive inflammatory and vascular evaluation, including computed tomography
angiogram of the chest and abdomen, was negative
for dissection, vascular abnormalities, or inflammation. She had slow but good recovery and was maintained off triptans and did not have any subsequent
neurological attacks over the next 4 years.
Migraine is a major public health issue that affected
about 1.04 billion individuals in 2016, with an estimated
45.1 million years lived with disability. Migraine treatment includes a wide range of therapeutic agents that are
either nonspecific such as acetaminophen, aspirin, and
other nonsteroidal anti-inflammatory drugs, or specific
including ergots and triptans.3 Different classes of triptans have been proven to be effective in treatment of
acute migraines of any severity.3,13 Naratriptan also has
a longer half-life of 5.5 hours that is believed to contribute to the lower recurrence of migraines with its use.4 In
addition, naratriptan has been shown to be an effective
short-term prophylactic treatment for perimenstrual
migraine, with a similar adverse effect severity and incidence compared with placebo.14 In general, and according to the manufacturer labeling; the most common
adverse effects (.2%) were paresthesia, nausea, dizziness, drowsiness, and fatigue.6
Migraine is an established stroke risk factor; one
systematic review showed that the pooled relative risk
for ischemic stroke for any type of migraine was 2.16
(95% confidence interval 1.89–2.48) with a higher risk
in patients with aura when compared with those without aura (2.27 vs. 1.83), respectively.7 Another review
showed similar results with higher pooled relative risk
of stroke in migraine with aura when compared with
those without aura (2.16 vs. 1.23), respectively.10 Association between PFO and migraines has been in debate
since 1995 when Del Sette et al showed a higher PFO
incidence in migraineurs when compared with normal
controls (41% vs. 16%).15 However, other studies failed
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FIGURE 1. (A and B) Sagittal and axial images of the thoracic spine respectively showing increased T2 signal on the
ventral aspect of the thoracic spine (T3–T6). (C and D) Axial and sagittal (arrow head) images of the thoracic spine
respectively showing diffusion restriction on the ventral aspect of the thoracic spine.

to show similar association.16 Recent literature studying the adverse cardiovascular outcomes of triptans
failed to show an increased risk of strokes in patients
using triptans.9,11,12 Nonetheless, the use of triptans in
patients with history of stroke is contraindicated.6
This case is the first reported case of naratriptaninduced spinal infarct secondary to high doses of naratriptan. Temporal relation to the excessive use of Naratriptan, typical anatomical anterior spinal artery
distribution on MRI with restricted diffusion on
diffusion-weighted imaging, and lack of alternative
diagnosis strengthen the causal relationship of triptan
and spinal infarction.
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